NEI Podcast

In this episode of our special pediatric psychopharmacology series, Dr. Jeffrey Strawn and Dr. Adelaide Robb explore the nuanced use of lithium in treating bipolar disorder among children and adolescents. Their discussion delves into critical aspects of lithium treatment, including carefully calibrated dosing regimens, comprehensive side effect management, and the essential role of parental involvement in treatment decisions. 

Jeffrey R. Strawn, MD is a Professor and Associate Vice Chair of Research in the Department of Psychiatry and Behavioral Neuroscience at the University of Cincinnati (UC) College of Medicine, the Assistant Director of Clinical and Translational Research in the Center for Clinical & Translational Science and Training at UC, and an Associate Professor in the Department of Pediatrics at UC and Cincinnati Children’s Hospital Medical Center. 

Adelaide S. Robb, MD is a psychopharmacologist who specializes in mood disorders, anxiety, and attention deficit disorder. She is Chief of the Division of Psychiatry and Behavioral Sciences at Children’s National Hospital in Washington, DC. 

Never miss an episode!🎙 SUBSCRIBE to the NEI Podcast– available on all your favorite platforms: https://nei.global/podcast  

Interested in Psychopharmacology?  Learn about the NEI Master Psychopharmacology Program: https://nei.global/mpp   

Stay updated with email alerts and join our conversations on social. Follow us on:  

• YouTube: https://nei.global/youtube  

• Instagram: https://nei.global/instagram  

• LinkedIn: https://nei.global/linkedin  

• Facebook: https://nei.global/facebook  

• X: https://nei.global/twitter  

This episode includes extended Q&A sessions that address your unanswered questions from the following presentations delivered at the 2024 Congress in Colorado Springs, Colorado: 

• (00:23) Panic On the Playground! Managing Social Anxiety in Pediatric Patients by Katherine Dahlsgaard, PhD, ABPP and Jeffrey Strawn, MD (Q&A with Dr. Dahlsgaard)  

• (15:12) Inflammatory Remarks: Our Evolving Understanding of the Role of Inflammation in Mental Health by Roger McIntyre, MD, FRCPC and Vladimir Maletic, MD, MS (Q&A with Dr. McIntyre)  

• (35:33) Wake Me Up Before You Go-Go: Strategies for Improving Sleep-Wake Issues by Thomas Schwartz, MD  

• (51:32) Beyond the Blues: Risk, Recognition, and Relief from Perinatal Mood and Anxiety Disorders by Lisa Tremayne, RN, PMH-C, CBC ([email protected]) 

Never miss an episode!🎙SUBSCRIBE to the NEI Podcast– available on all your favorite platforms: https://nei.global/podcast 

Interested in Psychopharmacology?  Learn about the NEI Master Psychopharmacology Program: https://nei.global/mpp  

Stay updated with email alerts and join our conversations on social. Follow us on: 

• YouTube: https://nei.global/youtube 

• Instagram: https://nei.global/instagram 

• LinkedIn: https://nei.global/linkedin 

• Facebook: https://nei.global/facebook 

• X: https://nei.global/twitter 

In this special episode of the NEI Podcast, Dr. Andy Cutler interviews the founder of NEI, Dr. Stephen Stahl about the origins of NEI and the NEI Congress. They also field personal and clinical questions submitted my podcast listeners and NEI members across social media! Tune in for an insightful and fun conversation celebrating 20 years of NEI Congress! 

Never miss an episode!🎙SUBSCRIBE to the NEI Podcast– available on all your favorite platforms: https://nei.global/podcast 

Interested in Psychopharmacology?  Learn about the NEI Master Psychopharmacology Program: https://nei.global/mpp  

Stay updated with email alerts and join our conversations on social. Follow us on: 

• YouTube: https://nei.global/youtube 

• Instagram: https://nei.global/instagram 

• LinkedIn: https://nei.global/linkedin 

• Facebook: https://nei.global/facebook 

• X: https://nei.global/twitter 

In this CME episode, Drs. Andrew Cutler and Roger McIntyre discuss the challenges and importance of diagnosing bipolar disorder as early as possible in the course of the illness. They also review strategies to achieve a correct diagnosis to provide the most efficacious and tolerable treatments available for bipolar disorder.

Target Audience: This activity has been developed for the healthcare team or individual prescriber specializing in mental health. All other healthcare team members interested in psychopharmacology are welcome for advanced study.

Learning Objectives: After completing this educational activity, you should be better able to:

• Employ effective screening tools and assessment strategies to enhance diagnostic accuracy and achieve early diagnosis of bipolar disorder
• Develop patient-centered treatment plans that incorporate current evidence and individual patient factors
• Utilize shared decision-making approaches to optimize treatment outcomes for patients with bipolar disorder

Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Activity Overview: This activity is available with audio and is best supported via a computer or device with current versions of the following browsers: Mozilla Firefox, Google Chrome, or Safari. A PDF reader is required for print publications. A post-test score of 70% or higher is required to receive CME/CE credit.   Estimated Time to Complete: 1 hour Released: November 01, 2024*   Expiration: October 31, 2027 *NEI maintains a record of participation for six (6) years.

CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click: https://nei.global/POD24-BD Credit Designations: The following are being offered for this activity:

• Physician: ACCME AMA PRA Category 1 Credits™
• NEI designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity
• Nurse: ANCC contact hours
• NEI designates this Enduring Material for a maximum of 1.0 ANCC contact hour
• Nurse Practitioner: ACCME AMA PRA Category 1 Credit™
• American Academy of Nurse Practitioners National Certification Program accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
• The content in this activity pertaining to pharmacology is worth 1.0 continuing education hour of pharmacotherapeutics.
• Pharmacy: ACPE application-based contact hours
• This internet enduring, knowledge-based activity has been approved for a maximum of 1.0 contact hour (.10 CEU).
• The official record of credit will be in the CPE Monitor system. Following ACPE Policy, NEI must transmit your claim to CPE Monitor within 60 days from the date you complete this CPE activity and is unable to report your claimed credit after this 60-day period.
• Physician Associate/Assistant: AAPA Category 1 CME credits
• NEI has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with the AAPA CME Criteria. This internet enduring activity is designated for 1.0 AAPA Category 1 credit. Approval is valid until OCtober 31, 2027. PAs should only claim credit commensurate with the extent of their participation.
• Psychology: APA CE credits
• Continuing Education (CE) credits for psychologists are provided through the co-sponsorship of the American Psychological Association (APA) Office of Continuing Education in Psychology (CEP). The APA CEP Office maintains responsibility for the content of the programs.
• Social Work: ASWB-ACE CE credits
• As a Jointly Accredited Organization, NEI is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. Regulatory boards are the final authority on courses accepted for continuing education credit. Social workers completing this internet enduring course receive 1 general continuing education credits.
• Non-Physician Member of the Healthcare Team: Certificate of Participation
• NEI awards hours of participation (consistent with the designated number of AMA PRA Category 1 Credit(s)™) to a participant who successfully completes this educational activity.
• Interprofessional Continuing Education: IPCE credit for learning and change
• This activity was planned by and for the healthcare team, and learners will receive 1 Interprofessional Continuing Education (IPCE) credit for learning and change.

Peer Review: The content was peer-reviewed by an MD, MPH specializing in forensics, psychosis, schizophrenia, mood disorders, anxiety, cognitive disorders — to ensure the scientific accuracy and medical relevance of information presented and its independence from commercial bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME/CE activity.

Disclosures: All individuals in a position to influence or control content are required to disclose any relevant financial relationships.

Faculty Author / Presenter Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry and Behavioral Sciences, Norton College of Medicine, State University of New York Upstate Medical University, Syracuse, New York Chief Medical Officer, Neuroscience Education Institute, Malvern, Pennsylvania Consultant/Advisor: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, Biogen, BioXcel, Boehringer Ingelheim, Brii Biosciences, Cerevel, Corium, Delpor, Evolution Research, Idorsia, Intra-Cellular, Ironshore, Janssen, Jazz, Karuna, Lundbeck, LivaNova, Luye, MapLight Therapeutics, Neumora, Neurocrine, NeuroSigma, Noven, Otsuka, Relmada, Reviva, Sage Therapeutics, Sumitomo (Sunovion), Supernus, Takeda, Teva, Tris Pharma, VistaGen Therapeutics Speakers Bureau: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, BioXcel, Corium, Idorsia, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sumitomot (Sunovion), Supernus, Takeda, Teva, Tris Pharma, Vanda Data Safety Monitoring Board (DSMB): COMPASS Pathways, Freedom Biosciences Faculty Author / Presenter Roger S. McIntyre, MD, FRCPC Professor, Departments of Psychiatry and of Pharmacology, University of Toronto, Toronto, Ontario, Canada CEO, Braxia Scientific Corp, Toronto, Ontario, Canada Grant/Research: Canadian Institutes of Health Research, China National Natural Research Foundation, Global Alliance for Chronic Diseases, Milken Institute Consultant/Advisor: Alkermes, Atai Life Sciences, Axsome, Bausch Health, Biogen, Eisai, Intra-Cellular, Janssen, Kris, Lundbeck, Mitsubishi Tanabe, Neumora Therapeutics, Neurocrine, NewBridge Pharmaceuticals, Novo Nordisk, Otsuka, Pfizer, Purdue, Sage, Sanofi, Sunovion, Takeda, Viatris The remaining Planning Committee members, Content Editors, Peer Reviewer, and NEI planners/staff have no financial relationships to disclose. NEI planners and staff include Caroline O’Brien, Gabriela Alarcón, PhD, Andrea Zimmerman, EdD, CHCP, and Brielle Calleo.

Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses.

Cultural Linguistic Competency and Implicit Bias: A variety of resources addressing cultural and linguistic competencies and strategies for understanding and reducing implicit bias can be found in this handout—download me.

Accessibility Statement

Contact Us: For questions regarding this educational activity, or to cancel your account, please email [email protected].

Support: This activity is supported by an unrestricted educational grant from Alkermes, Inc.

In this CME episode, Dr. Andy Cutler interviews Dr. Leslie Citrome about the impact of tardive dyskinesia on patient-reported outcomes and quality of life. They discuss how to correctly assess and diagnose tardive dyskinesia, as well as effective management strategies that incorporate the individual needs of patients. 

Target Audience: This activity has been developed for the healthcare team or individual prescriber specializing in mental health. All other healthcare team members interested in psychopharmacology are welcome for advanced study.

Learning Objectives: After completing this educational activity, you should be better able to:

• Understand the physical, psychological, social, and occupational impacts of tardive dyskinesia (TD) on patients
• Identify clinical tools and patient-reported outcome measures to assess the severity and impact of TD
• Formulate evidence-based treatment strategies for TD that enhance patient outcomes and quality of life

Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.   Activity Overview: This activity is available with audio and is best supported via a computer or device with current versions of the following browsers: Mozilla Firefox, Google Chrome, or Safari. A PDF reader is required for print publications. A post-test score of 70% or higher is required to receive CME/CE credit.   Estimated Time to Complete: 1 hour Released: October 23, 2024*   Expiration: October 22, 2027 *NEI maintains a record of participation for six (6) years.   CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click: https://nei.global/POD24-TD   Credit Designations: The following are being offered for this activity:

• Physician: ACCME AMA PRA Category 1 Credits™
• NEI designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity
• Nurse: ANCC contact hours
• NEI designates this Enduring Material for a maximum of 1.0 ANCC contact hour
• Nurse Practitioner: ACCME AMA PRA Category 1 Credit™
• American Academy of Nurse Practitioners National Certification Program accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
• The content in this activity pertaining to pharmacology is worth 1.0 continuing education hour of pharmacotherapeutics.
• Pharmacy: ACPE application-based contact hours
• This internet enduring, knowledge-based activity has been approved for a maximum of 1.0 contact hour (.10 CEU).
• The official record of credit will be in the CPE Monitor system. Following ACPE Policy, NEI must transmit your claim to CPE Monitor within 60 days from the date you complete this CPE activity and is unable to report your claimed credit after this 60-day period.
• Physician Associate/Assistant: AAPA Category 1 CME credits
• NEI has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with the AAPA CME Criteria. This internet enduring activity is designated for 1.0 AAPA Category 1 credit. Approval is valid until OCtober 22, 2027. PAs should only claim credit commensurate with the extent of their participation.
• Psychology: APA CE credits
• Continuing Education (CE) credits for psychologists are provided through the co-sponsorship of the American Psychological Association (APA) Office of Continuing Education in Psychology (CEP). The APA CEP Office maintains responsibility for the content of the programs.
• Social Work: ASWB-ACE CE credits
• As a Jointly Accredited Organization, NEI is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. Regulatory boards are the final authority on courses accepted for continuing education credit. Social workers completing this internet enduring course receive 1 general continuing education credits.
• Non-Physician Member of the Healthcare Team: Certificate of Participation
• NEI awards hours of participation (consistent with the designated number of AMA PRA Category 1 Credit(s)™) to a participant who successfully completes this educational activity.
• Interprofessional Continuing Education: IPCE credit for learning and change
• This activity was planned by and for the healthcare team, and learners will receive 1 Interprofessional Continuing Education (IPCE) credit for learning and change.

Peer Review: The content was peer-reviewed by an MD, MPH specializing in forensics, psychosis, schizophrenia, mood disorders, anxiety, cognitive disorders — to ensure the scientific accuracy and medical relevance of information presented and its independence from commercial bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME/CE activity.

Disclosures: All individuals in a position to influence or control content are required to disclose any relevant financial relationships.

Faculty Author / Presenter Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry and Behavioral Sciences, Norton College of Medicine, State University of New York Upstate Medical University, Syracuse, NY Chief Medical Officer, Neuroscience Education Institute, Malvern, PA Consultant/Advisor: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, Biogen, BioXcel, Boehringer Ingelheim, Brii Biosciences, Cerevel, Corium, Delpor, Evolution Research, Idorsia, Intra-Cellular, Ironshore, Janssen, Jazz, Karuna, Lundbeck, LivaNova, Luye, MapLight Therapeutics, Neumora, Neurocrine, NeuroSigma, Noven, Otsuka, Relmada, Reviva, Sage Therapeutics, Sumitomo (Sunovion), Supernus, Takeda, Teva, Tris Pharma, VistaGen Therapeutics Speakers Bureau: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, BioXcel, Corium, Idorsia, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sumitomot (Sunovion), Supernus, Takeda, Teva, Tris Pharma, Vanda Data Safety Monitoring Board (DSMB): COMPASS Pathways, Freedom Biosciences Faculty Author / Presenter Leslie Citrome, MD, MPH Clinical Professor, Department of Psychiatry and Behavioral Sciences, New York Medical College, Valhalla, NY Consultant/Advisor: AbbVie/Allergan, Acadia, Adamas, Alkermes, Angelini, Astellas, Avanir, Axsome, Biogen, BioXcel, Boehringer Ingelheim, Cadent Therapeutics, Cerevel, Clinilabs, COMPASS, Delpor, Eisai, Enteris BioPharma, HLS Therapeutics, Idorsia, INmune Bio, Impel, Intra-Cellular Therapies, Janssen, Karuna, Lundbeck, Luye, Lyndra, MapLight, Marvin, Medavante-ProPhase, Merck, Mitsubishi-Tanabe Pharma, Neumora, Neurocrine, Neurelis, Noema, Novartis, Noven, Otsuka, Ovid, Praxis, Recordati, Relmada, Reviva, Sage, Sumitomo/Sunovion, Supernus, Teva, University of Arizona, Vanda Speakers Bureau: AbbVie/Allergan, Acadia, Alkermes, Angelini, Axsome, BioXcel, Eisai, Idorsia, Intra-Cellular Therapies, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Recordati, Sage, Sunovion, Takeda, Teva Stockholder: Bristol-Myers Squibb, Eli Lilly, J & J, Merck, Pfizer, Reviva (options) The remaining Planning Committee members, Content Editors, Peer Reviewer, and NEI planners/staff have no financial relationships to disclose. NEI planners and staff include Caroline O’Brien, Gabriela Alarcón, PhD, Andrea Zimmerman, EdD, CHCP, and Brielle Calleo.

Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses.

Cultural Linguistic Competency and Implicit Bias: A variety of resources addressing cultural and linguistic competencies and strategies for understanding and reducing implicit bias can be found in this handout—download me.

Accessibility Statement

Contact Us: For questions regarding this educational activity, or to cancel your account, please email [email protected].

Support: This activity is supported by an unrestricted educational grant from Teva Pharmaceuticals.

In the first episode of a special pediatric psychopharmacology series hosted by Dr. Jeffrey Strawn, Dr. John Walkup joins the podcast to discuss deprescribing in pediatric patients. The conversation delves into the situations that warrant deprescribing from antidepressants, selecting the right time to do so, and dealing with relapse, as well as much more! 

Jeffrey R. Strawn, MD is a Professor and Associate Vice Chair of Research in the Department of Psychiatry and Behavioral Neuroscience at the University of Cincinnati (UC) College of Medicine, the Assistant Director of Clinical and Translational Research in the Center for Clinical & Translational Science and Training at UC, and an Associate Professor in the Department of Pediatrics at UC and Cincinnati Children’s Hospital Medical Center. 

John T. Walkup, MD is Head of the Pritzker Department of Psychiatry and Behavioral Health at Ann & Robert H. Lurie Children’s Hospital of Chicago and a Margaret C. Osterman Professor of Psychiatry and Behavioral Science. He also serves as Director of the Division of Child and Adolescent Psychiatry in the Department of Psychiatry and Behavioral Sciences at Northwestern University Feinberg School of Medicine. 

Never miss an episode!🎙 SUBSCRIBE to the NEI Podcast– available on all your favorite platforms: https://nei.global/podcast 

Interested in Psychopharmacology?  Learn about the NEI Master Psychopharmacology Program: https://nei.global/mpp   

Stay updated with email alerts and join our conversations on social. Follow us on:  

• YouTube: https://nei.global/youtube  

• Instagram: https://nei.global/instagram  

• LinkedIn: https://nei.global/linkedin  

• Facebook: https://nei.global/facebook  

• X: https://nei.global/twitter  

This Domestic Violence Awareness Month, we're revisiting an important topic: the often overlooked risk of traumatic brain injury (TBI) among victims of intimate partner violence. Our goal is to shed light on this highly vulnerable group that frequently goes unnoticed in discussions about TBI. By reexamining a previous episode released in March 2020, we aim to raise awareness about the significant dangers faced by those experiencing domestic abuse, particularly the risk of brain injuries resulting from physical violence in intimate relationships. 

Deb York, MSN, PMHNP-BC, APRN, CCRA is a board certified Psychiatric-Mental Health Nurse Practitioner practicing in Colorado Springs, Colorado. She completed her research certification as a Certified Clinical Research Associate at the Association of Clinical Research Professionals, and is the Director of Clinical Research at Mountain Mind.   

Her research focuses on conducting clinical trials to identify and evaluate novel psychopharmacological and neuroradiological interventions for traumatic brain injury, mood disorders, and pediatric psychiatric illnesses. Deb has over 25 years in the clinical trials industry conducting clinical research in pharmaceuticals & biologics, with a specialty in Women’s Health, CNS & psychiatric clinical trials. 

Never miss an episode!🎙SUBSCRIBE to the NEI Podcast– available on all your favorite platforms: https://nei.global/podcast 

Interested in Psychopharmacology?  Learn about the NEI Master Psychopharmacology Program: https://nei.global/mpp  

Stay updated with email alerts and join our conversations on social. Follow us on: 

• YouTube: https://nei.global/youtube 

• Instagram: https://nei.global/instagram 

• LinkedIn: https://nei.global/linkedin 

• Facebook: https://nei.global/facebook 

• X: https://nei.global/twitter 

Join Dr. Andy Cutler as he talks with Dr. Joan Striebel about the syndrome of catatonia, including its dynamic presentation, treating the underlying disorder, and why clinicians must raise their index of suspicion when evaluating symptoms that could indicate catatonia is present. 

Dr. Joan Striebel is a psychiatrist at the California Department of State Hospitals, which is the largest forensic mental health hospital system in the nation. 

 

Resources: 

Bush-Francis Catatonia Rating Scale Assessment Resources 

Catatonia and Its Treatments 

Catatonia: A Clinician’s Guide to Diagnosis and Treatment 

Catatonia: From Psychopathology to Neurobiology 

Guidelines for the management of catatonia 

 

Never miss an episode!🎙 SUBSCRIBE to the NEI Podcast– available on all your favorite platforms: https://nei.global/podcast 

Interested in Psychopharmacology?  Learn about the NEI Master Psychopharmacology Program: https://nei.global/mpp  

Stay updated with email alerts and join our conversations on social. Follow us on: 

• YouTube: https://nei.global/youtube 

• Instagram: https://nei.global/instagram 

• LinkedIn: https://nei.global/linkedin 

• Facebook: https://nei.global/facebook 

• X: https://nei.global/twitter 

In this CME episode, Dr. Andrew Cutler interviews Dr. Charles Vega about the challenges of identifying bipolar disorder in primary care and how to over come them. They also discuss strategies for initiating and managing pharmacological treatment long term in collaboration with patients and psychiatric specialists.

Target Audience: This activity has been developed for the healthcare team or individual prescriber specializing in mental health. All other healthcare team members interested in psychopharmacology are welcome for advanced study.

Learning Objective: After completing this educational activity, you should be better able to:

• Identify the key symptoms and diagnostic criteria for bipolar disorder to accurately screen and diagnose patients presenting in primary care settings
• Describe strategies for initiating and managing pharmacological treatment of bipolar disorder, including appropriate use of mood stabilizers, antipsychotics, and monitoring for side effects and adherence
• Explain the role of the primary care provider in coordinating care for bipolar disorder patients, including providing psychoeducation, determining appropriate level of care, and collaborating with mental health specialists when needed

Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.   Activity Overview: This activity is available with audio and is best supported via a computer or device with current versions of the following browsers: Mozilla Firefox, Google Chrome, or Safari. A PDF reader is required for print publications. A post-test score of 70% or higher is required to receive CME/CE credit.   Estimated Time to Complete: 45 minutes Released: September 04, 2024*   Expiration: September 03, 2027 *NEI maintains a record of participation for six (6) years.

CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click: https://nei.global/POD24-PrimCare Credit Designations: The following are being offered for this activity:

• Physician: ACCME AMA PRA Category 1 Credits™
• NEI designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity
• Nurse: ANCC contact hours
• NEI designates this Enduring Material for a maximum of 0.75 ANCC contact hour
• Nurse Practitioner: ACCME AMA PRA Category 1 Credits™
• American Academy of Nurse Practitioners National Certification Program accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
• The content in this activity pertaining to pharmacology is worth 0.75 continuing education hour of pharmacotherapeutics.
• Pharmacy: ACPE application-based contact hours
• This internet enduring, knowledge-based activity has been approved for a maximum of 0.75 contact hour (.075 CEU).
• The official record of credit will be in the CPE Monitor system. Following ACPE Policy, NEI must transmit your claim to CPE Monitor within 60 days from the date you complete this CPE activity and is unable to report your claimed credit after this 60-day period.
• Physician Associate/Assistant: AAPA Category 1 CME credits
• NEI has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with the AAPA CME Criteria. This internet enduring activity is designated for 0.75 AAPA Category 1 credit. Approval is valid until September 03, 2027. PAs should only claim credit commensurate with the extent of their participation.
• Non-Physician Member of the Healthcare Team: Certificate of Participation
• NEI awards hours of participation (consistent with the designated number of AMA PRA Category 1 Credit™) to a participant who successfully completes this educational activity.
• Interprofessional Continuing Education: IPCE credit for learning and change
• This activity was planned by and for the healthcare team, and learners will receive 0.75 Interprofessional Continuing Education (IPCE) credit for learning and change.

Peer Review: The content was peer-reviewed by an MD, MPH specializing in forensics, psychosis, schizophrenia, mood disorders, anxiety, cognitive disorders — to ensure the scientific accuracy and medical relevance of information presented and its independence from commercial bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME/CE activity.

Disclosures: All individuals in a position to influence or control content are required to disclose any relevant financial relationships. Any relevant financial relationships were mitigated prior to the activity being planned, developed, or presented. Disclosures are from the original live presentation, unless otherwise noted.

Faculty Author / Presenter Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry and Behavioral Sciences, Norton College of Medicine, State University of New York Upstate Medical University, Syracuse, NYChief Medical Officer, Neuroscience Education Institute, Malvern, PA

Consultant/Advisor: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, Biogen, BioXcel, Boehringer Ingelheim, Brii Biosciences, Cerevel, Corium, Delpor, Evolution Research, Idorsia, Intra-Cellular, Ironshore, Janssen, Jazz, Karuna, Lundbeck, LivaNova, Luye, MapLight Therapeutics, Neumora, Neurocrine, NeuroSigma, Noven, Otsuka, Relmada, Reviva, Sage Therapeutics, Sumitomo (Sunovion), Supernus, Takeda, Teva, Tris Pharma, VistaGen Therapeutics Speakers Bureau: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, BioXcel, Corium, Idorsia, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sumitomot (Sunovion), Supernus, Takeda, Teva, Tris Pharma, Vanda Data Safety Monitoring Board (DSMB): COMPASS Pathways, Freedom Biosciences Faculty Author / Presenter Charles P. Vega, MD Clinical Professor, School of Medicine, University of California - Irvine, Orange, CA

Consultant/Advisor: Boehringer Ingelheim, Exact Sciences The remaining Planning Committee member(s), Content Editor(s), Peer Reviewer(s), and NEI planners/staff have no financial relationships to disclose. NEI planners and staff include Gabriela Alarcón, PhD, Andrea Zimmerman, EdD, Samantha Joy, and Brielle Calleo.

Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses.

Cultural Linguistic Competency and Implicit Bias: A variety of resources addressing cultural and linguistic competencies and strategies for understanding and reducing implicit bias can be found in this handout—download me.

Accessibility Statement

Contact Us: For questions regarding this educational activity, or to cancel your account, please email [email protected].

Support: This activity is supported solely by the provider, NEI.

What are the primary barriers to clozapine utilization in the United States, and how do these barriers impact patient care? What are some common misconceptions or negative attitudes among prescribers regarding clozapine, and how can these be addressed? What are some effective strategies for improving the management of clozapine’s side effects to encourage its use? What strategies can be implemented to improve education and awareness about clozapine? 

Brought to you by the NEI Podcast, the PsychopharmaStahlogy Show tackles the most novel, exciting, and controversial topics in psychopharmacology in a series of themes. This theme is on underutilized psychotropic drugs. 

Today, Dr. Andy Cutler interviews Dr. Jonathan Meyer and Dr. Stephen Stahl about factors that have led to the underutilization of clozapine in psychiatry. 

Let’s listen to Part 3 of our theme: Underutilized Psychiatric Drugs. 

Subscribe to the NEI Podcast, so that you don’t miss another episode! 

Resources 

The Clozapine Handbook  

Clozapine titrations paper (see Supplementary Material):  

de Leon J et al. Pharmacopsychiatry 2022;55(2):73-86. 

FDA committees meeting to discuss reevaluation of the Clozapine REMS program (November 19, 2024): click here.